4 Undervalued Pharmaceuticals Stocks for Thursday, November 07
Discover the top 4 undervalued Pharmaceuticals stocks for Thursday, November 07 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Commentary & Analysis
4 Undervalued Pharmaceuticals Stocks for Tuesday, September 17
Discover the top 4 undervalued Pharmaceuticals stocks for Tuesday, September 17 based on AAII’s Stock Grades.Eunice Kim
6 Undervalued Pharmaceuticals Stocks for Friday, August 09
Discover the top 6 undervalued Pharmaceuticals stocks for Friday, August 09 based on AAII’s Stock Grades.Eunice Kim
7 Undervalued Pharmaceuticals Stocks for Tuesday, June 11
Discover the top 7 undervalued Pharmaceuticals stocks for Tuesday, June 11 based on AAII’s Stock Grades.Grace Malone
5 Undervalued Pharmaceuticals Stocks for Friday, April 12
Discover the top 5 undervalued Pharmaceuticals stocks for Friday, April 12 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $23.1 | $569.9 | 11% |
|
| Shares Out (Mil) | 10.5 | 44.8 | 21% |
|
| Institutional Ownership | 76.3% | 84.6% | 46% |
|
| Float (Mil) | 7.6 | 45.1 | 16% |
|
| Beta | 0.25 | 0.67 | 15% |
|
| Avg Daily Volume (000s) | 21 | 294 | 21% |
|
| Price Change (52-week) |
(15.4%) | 65.2% | 34% |
|
| Growth | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.2% | 6.7% | 80% |
|
| Net Income (5yr) | 0.0% | (2.0%) | 40% |
|
| EPS (5yr) | 48.6% | 14.9% | 92 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (59.7%) | (14.9%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.350) | ($1.135) | ($0.075) | |
| Month Ago EPS | ($0.350) | ($1.135) | ($0.075) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.305) | ($1.240) | ($0.050) | |
| Year/Year Chg | (34.5%) | (49.7%) | (146.5%) | |
| Financials | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $57 | $230 | 21% |
|
| Net Income (TTM) (Mil) | ($34) | ($11) | 19% |
|
| EPS (TTM) | ($3.705) | ($0.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | $2 | ($6) | 34% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $11 | $7 | 28% |
|
| Enterprise Value (Q1) (Mil) | $20 | $493 | 11% |
|
| Valuation | AYTU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.66 | 2.89 | 12% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.8% | 65.9% | 77% |
|
| Net Margin | (60.2%) | (0.2%) | 10% |
|
| ROA | (28.9%) | (25.5%) | 17% |
|
| ROE | (97.2%) | (21.4%) | 10% |
|
| Liabilities to Assets | 68.5% | 35.5% | 64% |
|
| F-Score | 3 | 3 | na |
|
Aytu BioPharma, Inc. did not pass any screens on 7/30/2026.
